| Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial A Tutt, M Robson, JE Garber, SM Domchek, MW Audeh, JN Weitzel, ... The Lancet 376 (9737), 235-244, 2010 | 2188 | 2010 |
| 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial I Smith, M Procter, RD Gelber, S Guillaume, A Feyereislova, M Dowsett, ... The lancet 369 (9555), 29-36, 2007 | 1975 | 2007 |
| Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. A Webb, D Cunningham, JH Scarffe, P Harper, A Norman, JK Joffe, ... Journal of Clinical Oncology 15 (1), 261-267, 1997 | 1172 | 1997 |
| Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98 AS Coates, A Keshaviah, B Thürlimann, H Mouridsen, L Mauriac, ... Journal of clinical oncology 25 (5), 486-492, 2007 | 1153 | 2007 |
| Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2–positive, hormone receptor … B Kaufman, JR Mackey, MR Clemens, PP Bapsy, A Vaid, A Wardley, ... Journal of Clinical Oncology 27 (33), 5529-5537, 2009 | 1123 | 2009 |
| Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2–negative metastatic … DW Miles, A Chan, LY Dirix, J Cortés, X Pivot, P Tomczak, T Delozier, ... Journal of clinical oncology 28 (20), 3239-3247, 2010 | 1089 | 2010 |
| Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial A Tutt, H Tovey, MCU Cheang, S Kernaghan, L Kilburn, P Gazinska, ... Nature medicine 24 (5), 628-637, 2018 | 865 | 2018 |
| Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer that progressed during prior … J Baselga, KA Gelmon, S Verma, A Wardley, PF Conte, D Miles, G Bianchi, ... Journal of clinical oncology 28 (7), 1138-1144, 2010 | 847 | 2010 |
| Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer NU Lin, V Diéras, D Paul, D Lossignol, C Christodoulou, HJ Stemmler, ... Clinical cancer research 15 (4), 1452-1459, 2009 | 755 | 2009 |
| Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2−, node-positive, high-risk, early breast cancer (monarchE) SRD Johnston, N Harbeck, R Hegg, M Toi, M Martin, ZM Shao, QY Zhang, ... Journal of Clinical Oncology 38 (34), 3987-3998, 2020 | 675 | 2020 |
| Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally … D Miles, J Gligorov, F André, D Cameron, A Schneeweiss, C Barrios, B Xu, ... Annals of Oncology 32 (8), 994-1004, 2021 | 489 | 2021 |
| Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer AJ Clayton, S Danson, S Jolly, WDJ Ryder, PA Burt, AL Stewart, ... British journal of cancer 91 (4), 639-643, 2004 | 481 | 2004 |
| Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical … MM Regan, P Neven, A Giobbie-Hurder, A Goldhirsch, B Ejlertsen, ... The lancet oncology 12 (12), 1101-1108, 2011 | 468 | 2011 |
| Randomized phase II study of the anti–epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple … J Baselga, P Gómez, R Greil, S Braga, MA Climent, AM Wardley, ... Journal of clinical oncology 31 (20), 2586-2592, 2013 | 445 | 2013 |
| Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial NU Lin, V Borges, C Anders, RK Murthy, E Paplomata, E Hamilton, ... Journal of Clinical Oncology 38 (23), 2610-2619, 2020 | 429 | 2020 |
| Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor … SRD Johnston, LS Kilburn, P Ellis, D Dodwell, D Cameron, L Hayward, ... The Lancet Oncology 14 (10), 989-998, 2013 | 332 | 2013 |
| Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study N Harbeck, P Rastogi, M Martin, SM Tolaney, ZM Shao, PA Fasching, ... Annals of Oncology 32 (12), 1571-1581, 2021 | 323 | 2021 |
| Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring AL Jones, M Barlow, PJ Barrett-Lee, PA Canney, IM Gilmour, SD Robb, ... British journal of cancer 100 (5), 684-692, 2009 | 304 | 2009 |
| 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial HM Earl, L Hiller, AL Vallier, S Loi, K McAdam, L Hughes-Davies, ... The Lancet 393 (10191), 2599-2612, 2019 | 301 | 2019 |
| Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haemopoietic progenitor rescue AM Wardley, GC Jayson, R Swindell, GR Morgenstern, J Chang, R Bloor, ... British journal of haematology 110 (2), 292-299, 2000 | 300 | 2000 |
dave cameronProfessor of Oncology, University of EdinburghVerified email at ed.ac.uk
